苏州大学医学中心/苏州大学附属第四医院/苏州市独墅湖医院药学部,江苏 苏州 215000
Received:11 May 2026,
Revised:2026-08-31,
Accepted:14 September 2026,
Published:15 October 2026
移动端阅览
洪华东,包健安,马晶晶.奥沙利铂所致肝窦阻塞综合征的多维度临床评估与转归分析 [J].中国药房,2026,37(19):2560-2565.
HONG Huadong,BAO Jian’an,MA Jingjing.Multidimensional clinical assessment and outcome analysis of oxaliplatin-induced hepatic sinusoidal obstruction syndrome[J].ZHONGGUO YAOFANG,2026,37(19):2560-2565.
洪华东,包健安,马晶晶.奥沙利铂所致肝窦阻塞综合征的多维度临床评估与转归分析 [J].中国药房,2026,37(19):2560-2565. DOI: 10.6039/j.issn.1001-0408.2026.19.13.
HONG Huadong,BAO Jian’an,MA Jingjing.Multidimensional clinical assessment and outcome analysis of oxaliplatin-induced hepatic sinusoidal obstruction syndrome[J].ZHONGGUO YAOFANG,2026,37(19):2560-2565. DOI: 10.6039/j.issn.1001-0408.2026.19.13.
目的
2
提高临床对奥沙利铂所致肝窦阻塞综合征(HSOS)的识别与管理水平。
方法
2
对PubMed、Web of Science、Embase、中国知网、维普网、万方医学数据库进行系统检索,收集奥沙利铂所致HSOS病例,同时纳入苏州大学附属第四医院(简称“本院”)收治的典型病例,系统分析奥沙利铂所致HSOS的临床特征、实验室检查指标、影像学表现、治疗及预后等,并按化疗方案和患者性别进行亚组分析。
结果
2
共收集到32例奥沙利铂所致HSOS病例(文献31例、本院1例)。其中,男、女各16例,中位年龄58.5岁,中位发病时间为168 d。最常见的实验室检查异常为碱性磷酸酶(ALP)/
γ
-谷氨酰转移酶(GGT)升高(占报告病例的69.2%,9/13),部分患者伴转氨酶升高及血小板减少。影像学表现包括脾肿大(37.5%,12/32)、肝内低密度灶(28.1%,9/32)及门脉高压征象(21.9%,7/32)等。治疗以停用奥沙利铂为主,辅以对症支持治疗或肝切除术,患者总体好转率为84.0%(21/25)。亚组分析结果显示,在使用FOLFOX方案的患者中,有36.8%的患者在168 d内出现症状,显著低于使用其他方案的患者占比(83.3%)(
P
<0.012 5)。
结论
2
奥沙利铂所致HSOS常表现为ALP/GGT升高与脾肿大,影像学上的低密度灶是鉴别诊断的重点,停药并对症支持治疗后多数患者病情改善。临床应重视早期识别该并发症,密切监测患者肝功能和影像学变化。
OBJECTIVE
2
To improve the clinical recognition and management of oxaliplatin-induced hepatic sinusoidal obstruction syndrome (HSOS).
METHODS
2
A systematic search was conducted in PubMed, Web of Science, Embase, CNKI, VIP, and Wanfang Medical Database to collect cases of oxaliplatin-induced HSOS. Typical cases admitted to the Fourth Affiliated Hospital of Soochow University (hereinafter referred to as “our hospital”) were also included. The clinical characteristics, laboratory findings, imaging manifestations, treatment, and prognosis of oxaliplatin-induced HSOS were systematically analyzed, and subgroup analyses were performed according to chemotherapy regimen and patient sex.
RESULTS
2
A total of 32 cases of oxaliplatin-induced HSOS were collected (31 from the literature and 1 from our hospital). Among them, there were 16 males and 16 females, with a median age of 58.5 years and a median time to onset of 168 days. The most common laboratory abnormality was elevated alkaline phosphatase (ALP)/
γ
-glutamyl transferase (GGT) (accounting for 69.2% of reported cases, 9/13), and some patients had elevated transaminases and thrombocytopenia. Imaging findings included splenomegaly (37.5%, 12/32), intrahepatic hypodense lesions (28.1%, 9/32), signs of portal hypertension (21.9%, 7/32), etc. Treatment mainly consisted of discontinuation of oxaliplatin, supplemented with symptomatic supportive treatment or liver resection. The overall improvement rate of patients was 84.0% (21/25). Subgroup analysis showed that among patients receiving the FOLFOX regimen, 36.8% developed symptoms within 168 days, which was significantly lower than the proportion of patients receiving other regimens (83.3%) (
P
<0.012 5).
CONCLUSIONS
2
Oxaliplatin-induced HSOS often presents with elevated ALP/GGT and splenomegaly. Hypodense lesions on imaging are a key point in differential diagnosis. Most patients improve after discontinuation of oxaliplatin and symptomatic supportive treatment. Clinically, emphasis should be placed on early recognition of this complication and close monitoring of liver function and imaging changes.
Valla D C , Cazals-Hatem D . Sinusoidal obstruction syndrome [J ] . Clin Res Hepatol Gastroenterol , 2016 , 40 ( 4 ): 378 - 385 .
Nalbantoglu I , Jr Tan B R , Linehan D C , et al . Histological features and severity of oxaliplatin-induced liver injury and clinical associations [J ] . J Digest Diseases , 2014 , 15 ( 10 ): 553 - 560 .
Cha D I , Song K D , Ha S Y , et al . Long-term follow-up of oxaliplatin-induced liver damage in patients with colorectal cancer [J ] . Br J Radiol , 2021 , 94 ( 1123 ): 20210352 .
Overman M J , Maru D M , Charnsangavej C , et al . Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury [J ] . J Clin Oncol , 2010 , 28 ( 15 ): 2549 - 2555 .
付雪林 , 邓军 , 黄小宁 , 等 . 奥沙利铂致肝窦阻塞综合征患者脾脏体积和肝纤维化指数变化分析 [J ] . 肝脏 , 2021 , 26 ( 5 ): 550 - 553 .
Honda S , Tsujimoto M , Minegaki T , et al . A case of idiosyncratic liver injury after oxaliplatin-induced thrombocytopenia [J ] . J Clin Pharm Ther , 2020 , 45 ( 2 ): 373 - 375 .
Vietor N O , George B J . Oxaliplatin-induced hepatocellular injury and ototoxicity:a review of the literature and report of unusual side effects of a commonly used chemotherapeutic agent [J ] . J Oncol Pharm Pract , 2012 , 18 ( 3 ): 355 - 359 .
Shimagaki T , Sugimachi K , Mano Y , et al . Simple systemic index associated with oxaliplatin-induced liver damage can be a novel biomarker to predict prognosis after resection of colorectal liver metastasis [J ] . Ann Gastroenterol Surg , 2022 , 6 ( 6 ): 813 - 822 .
Suzuki A , Björnsson E S . Exploring the influence of sex on idiosyncratic DILI:impact on risk assessment [J ] . Expert Opin Drug Metab Toxicol , 2026 , 22 ( 5 ): 303 - 312 .
Liu F , Cao X , Ye J , et al . Oxaliplatin-induced hepatic sinusoidal obstruction syndrome in a patient with gastric cancer:a case report [J ] . Mol Clin Oncol , 2018 , 8 ( 3 ): 453 - 456 .
Alexandrino H , Oliveira D , Cipriano M A , et al . Oxaliplatin toxicity presenting as a liver nodule:a case report [J ] . BMC Cancer , 2015 , 15 ( 1 ): 247 .
Kobayashi S , Okudaira S , Kobayashi K , et al . Peripheral hepatic sinusoidal obstruction syndrome due to oxaliplatin-based chemotherapy [J ] . Clin Case Rep , 2019 , 7 ( 2 ): 394 - 396 .
Sarathy V , Kothandath Shankar R K , Mufti S S , et al . FOLFOX and capecitabine-induced hepatic granuloma mimicking metastasis in a rectal cancer patient [J ] . BMJ Case Rep , 2020 , 13 ( 3 ): e232628 .
Uchino K , Fujisawa M , Watanabe T , et al . Oxaliplatin-induced liver injury mimicking metastatic tumor on images:a case report [J ] . Jpn J Clin Oncol , 2013 , 43 ( 10 ): 1034 - 1038 .
Kawai T , Yamazaki S , Iwama A , et al . Focal sinusoidal obstruction syndrome caused by oxaliplatin-induced chemotherapy:a case report [J ] . Hepat Mon , 2016 , 16 ( 9 ): e37572 .
Arakawa Y , Shimada M , Utsunomya T , et al . Oxaliplatin-related sinusoidal obstruction syndrome mimicking metastatic liver tumors [J ] . Hepatol Res , 2013 , 43 ( 6 ): 685 - 689 .
Arotçarena R , Calès V , Berthelémy P , et al . Severe sinusoidal lesions:a serious and overlooked complication of oxaliplatin-containing chemotherapy [J ] . Gastroenterol Clin Biol , 2006 , 30 ( 11 ): 1313 - 1316 .
Slade J H , Alattar M L , Fogelman D R , et al . Portal hypertension associated with oxaliplatin administration:clinical manifestations of hepatic sinusoidal injury [J ] . Clin Colorectal Cancer , 2009 , 8 ( 4 ): 225 - 230 .
林建光 , 陈平 , 许天文 . 奥沙利铂化疗导致类瘤样肝损伤1例 [J ] . 中国肿瘤临床 , 2021 , 48 ( 19 ): 1023 - 1024 .
Ünal E , Karaosmanoğlu A D , Ozmen M N , et al . Hepatobiliary phase liver MR imaging findings after oxaliplatin-based chemotherapy in cancer patients [J ] . Abdom Radiol , 2018 , 43 ( 9 ): 2321 - 2328 .
Choi J H , Won Y W , Kim H S , et al . Oxaliplatin-induced sinusoidal obstruction syndrome mimicking metastatic colon cancer in the liver [J ] . Oncol Lett , 2016 , 11 ( 4 ): 2861 - 2864 .
Tomonaga K , Kurumiya Y , Sekiguchi H , et al . A case of metastatic liver cancer where resection was questioned due to oxaliplatin-induced sinusoidal occlusion syndrome [J ] . J Cancer Chemother , 2018 , 45 ( 6 ): 989 - 992 .
Bernichon E , Daguenet E , Molla C , et al . Sinusoidal obstruction syndrome/veno-occlusive disease complication in lymphoma patients treated with oxaliplatin-based regimen:a case series report [J ] . Curr Res Transl Med , 2018 , 66 ( 4 ): 107 - 110 .
Ishizaki T , Abe T , Koyanagi Y , et al . A case of liver failure due to hepatic toxicity from mFOLFOX-6 following resection of liver metastases from colorectal cancer [J ] . J Cancer Chemother , 2007 , 34 ( 6 ): 945 - 948 .
Fuentes-Lacouture M C , Barrera-Garavito E C , Gomez A , et al . Non-cirrhotic portal hypertension in a patient with colonic carcinoma treated with oxaliplatin [J ] . J Med Cases , 2021 , 12 ( 3 ): 99 - 101 .
Ganta N , Prasad A , Aknouk M , et al . A case report of nodular regenerative hyperplasia and non-cirrhotic portal hypertension post oxaliplatin chemotherapy [J ] . Cureus , 2022 , 14 ( 9 ): e28740 .
Seo A N , Kim H . Sinusoidal obstruction syndrome after oxaliplatin-based chemotherapy [J ] . Clin Mol Hepatol , 2014 , 20 ( 1 ): 81 .
Ichimaru T , Sakamoto T , Amagai T . Oxaliplatin-induced portal hypertension manifesting as portosystemic shunt:a case report and review of sinusoidal obstruction syndrome in gastric cancer [J ] . DEN Open , 2025 , 5 : e70109 .
Szczepaniak P , Mikolajczyk T P , Jozefczuk E , et al . Menopausal status associated with docetaxel-induced vascular dysfunction in breast cancer patients [J ] . JACC , 2026 , 87 ( 6 ): 685 - 700 .
Zhu C , Ren X H , Liu D , et al . Oxaliplatin-induced hepatic sinusoidal obstruction syndrome [J ] . Toxicology , 2021 , 460 : 152882 .
Valdivielso J M , Jacobs-Cachá C , Soler M J . Sex hormones and their influence on chronic kidney disease [J ] . Curr Opin Nephrol Hypertens , 2019 , 28 ( 1 ): 1 - 9 .
0
Views
0
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621
